Symtuza 800 mg/150 mg/200 mg/10 mg filmsko obložene tablete Słowenia - słoweński - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

symtuza 800 mg/150 mg/200 mg/10 mg filmsko obložene tablete

janssen-cilag international nv - darunavir, emtricitabin, kobicistat, alafenamidtenofovirat - filmsko obložena tableta - darunavir 800 mg / 1 tableta; emtricitabin 200 mg / 1 tableta; kobicistat 150 mg / 1 tableta; alafenamidtenofovirat 10 mg / 1 tableta - -

Evotaz Unia Europejska - słoweński - EMA (European Medicines Agency)

evotaz

bristol-myers squibb pharma eeig - cobicistat, atazanavir - okužbe z virusom hiv - antivirusi za sistemsko uporabo - evotaz is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-1 infected adults and adolescents (aged 12 years and older weighing at least 35 kg) without known mutations associated with resistance to atazanavir (see sections 4. 4 in 5.

Darunavir Mylan Unia Europejska - słoweński - EMA (European Medicines Agency)

darunavir mylan

mylan pharmaceuticals limited - darunavir - okužbe z virusom hiv - antivirusi za sistemsko uporabo - darunavir, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv-1) infection (see section 4. darunavir mylan 75 mg, 150 mg, 300 mg and 600 mg tablets may be used to provide suitable dose regimens (see section 4. 2):za zdravljenje okužbe z virusom hiv-1 okužba v protiretrovirusno zdravljenje (art)-izkušeni odraslih bolnikih, vključno s tistimi, ki so bili zelo pre-obravnava. za zdravljenje okužbe z virusom hiv-1 okužba pri pediatričnih bolnikih od starosti 3 let in najmanj 15 kg telesne teže. pri odločanju za uvedbo zdravljenja z darunavir co-daje z nizkim odmerkom ritonavir, previdni, upoštevati je treba zdravljenje zgodovino posameznih bolnikov in vzorcev mutacije, povezane z različnimi agenti. genotypic or phenotypic testing (when available) and treatment history should guide the use of darunavir (see sections 4. 2, 4. 4 in 5. darunavir co-daje z nizkim odmerkom ritonavir je navedeno v kombinaciji z drugimi protiretrovirusnimi zdravili za zdravljenje bolnikov z virusom humane imunske pomanjkljivosti (hiv-1) okužbe.  darunavir co-administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg) (see section 4.  darunavir mylan 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are: antiretroviral therapy (art)-naïve (see section 4.  art-experienced with no darunavir resistance associated mutations (drv-rams) and who have plasma hiv-1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 10⁶/l. pri odločanju za uvedbo zdravljenja z darunavir v takih art-izkušeni bolniki, genotipa testiranje mora vodnik za uporabo darunavir (glej točki 4. 2, 4. 3, 4. 4 in 5.

Vemlidy Unia Europejska - słoweński - EMA (European Medicines Agency)

vemlidy

gilead sciences ireland uc - tenofovir alafenamid fumarat - hepatitis b - antivirusi za sistemsko uporabo - vemlidy is indicated for the treatment of chronic hepatitis b (chb) in adults and paediatric patients 6 years of age and older weighing at least 25 kg (see section 5.

Abakavir/lamivudin STADA 600 mg/300 mg filmsko obložene tablete Słowenia - słoweński - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

abakavir/lamivudin stada 600 mg/300 mg filmsko obložene tablete

stada arzneimittel ag - abakavir, lamivudin - filmsko obložena tableta - abakavir 600 mg / 1 tableta; lamivudin 300 mg / 1 tableta - lamivudin in abakavir

Abakavir/lamivudin Sandoz 600 mg/300 mg filmsko obložene tablete Słowenia - słoweński - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

abakavir/lamivudin sandoz 600 mg/300 mg filmsko obložene tablete

sandoz d.d. - abakavir, lamivudin - filmsko obložena tableta - abakavir 600 mg / 1 tableta; lamivudin 300 mg / 1 tableta - lamivudin in abakavir

Abakavir/lamivudin Sandoz 600 mg/300 mg filmsko obložene tablete Słowenia - słoweński - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

abakavir/lamivudin sandoz 600 mg/300 mg filmsko obložene tablete

sandoz d.d. - abakavir, lamivudin - filmsko obložena tableta - abakavir 600 mg / 1 tableta; lamivudin 300 mg / 1 tableta - lamivudin in abakavir

Valganciklovir Lek 450 mg filmsko obložene tablete Słowenia - słoweński - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

valganciklovir lek 450 mg filmsko obložene tablete

lek d.d. - valganciklovir - filmsko obložena tableta - valganciklovir 450 mg / 1 tableta - valganciklovir

Valganciklovir Stada 450 mg filmsko obložene tablete Słowenia - słoweński - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

valganciklovir stada 450 mg filmsko obložene tablete

stada arzneimittel ag - valganciklovir - filmsko obložena tableta - valganciklovir 450 mg / 1 tableta - valganciklovir

Adempas Unia Europejska - słoweński - EMA (European Medicines Agency)

adempas

bayer ag - riociguat - hipertenzija, pljučnica - antihipertenzivi za pljučno arterijsko hipertenzijo - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. učinkovitosti je bil prikazan v pah prebivalstva, vključno z aetiologies z idiopatsko ali dedne pah ali pah, povezanih z vezivnega tkiva bolezni. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.